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Introduction: Remote ischaemic preconditioning (RIPC) refers to non-lethal repeated bouts 
of ischaemia followed by reperfusion applied to a vascular bed, tissue or organ rendering 
protection to future ischaemic events. RIPC has been reported to enhance functional recovery 
from heart attacks and strokes, as well as improve conduit artery and microvessel function. 
Remarkably, very few human studies have examined the impact of RIPC on cerebral blood 
flow (CBF) or cerebrovascular function.  The overall aim of this thesis was to assess, in 
healthy individuals, the impact of bilateral arm RIPC or SHAM on resting CBF, 
cerebrovascular reactivity, cerebral autoregulation, and autoregulation during hypercapnia.  
Methods: Nine healthy participants (age 32.6±11.1 yrs; BMI 25.9±4.4 kg/m
2
) underwent two 
laboratory visits; RIPC and SHAM. RIPC consisted of 4 x 5 min periods of cuff inflation (to 
200 mmHg) around the upper arm, with cuff inflation alternated between arms every 5 mins. 
SHAM consisted of the same protocol, but with cuff inflation to a pressure of 10 mmHg. 
CBF was measured using transcranial Doppler ultrasonography. Cerebral autoregulation was 
assessed using the squat to stand technique (5 second squat-5 second stand) while cerebral 
CO2 reactivity was assessed via a period of hypercapnia involving inhalation of 5% CO2. 
Finally, cerebral autoregulation was again assessed during hypercapnia. 
Results: CBF was not affected during either RIPC or SHAM (P>0.05). RIPC did not 
significantly affect cerebral autoregulation or CO2 reactivity, compared to SHAM (P>0.05). 
Hypercapnia reduced transfer function phase (39 to 16) radians during autoregulation, with 
no difference between the IPC and Sham conditions.  
Conclusion: These data indicate that an acute bout of bilateral RIPC does not affect CBF, 
cerebral autoregulation or cerebral reactivity. Additionally, an acute bout of RIPC does not 
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Ischaemic preconditioning (IPC) refers to the phenomenon whereby 3-4 brief periods of 
ischaemia, followed by tissue reperfusion, confers subsequent protection against the 
magnitude of tissue injury following ischaemia. This concept was introduced 30 years ago in 
a study which demonstrated that cycles of ischaemia and reperfusion of coronary arteries are 
able to protect the myocardium from subsequent prolonged ischaemia and reperfusion, 
leading to a reduction in infarct size (Murry et al., 1986). A follow-up study, by Przyklenk 
and co-workers (Przyklenk et al., 1993), demonstrated that cycles of coronary ischaemia and 
reperfusion also protect remote cardiac tissue not directly exposed to the ischaemia-
reperfusion cycles. This study stimulated substantial research that resulted in the clinical 
application of IPC of a limb to protect remote tissue and/or organs, such as the heart, against 
the magnitude of tissue loss following an ischaemic event (Pickard et al., 2015). A reduction 
in myocardial damage by remote IPC (RIPC), including improvement in clinical outcomes, 
has been shown when applied in patients prior to cardiac surgery (Thielmann et al., 2013) and 
in patients with suspected myocardial infarction treated with RIPC during ambulance 
transition (Botker et al., 2010).  
A second potential benefit of RIPC has emerged from studies that have explored the effects 
of repeated RIPC (i.e. daily episodes of the 4 bouts of ischemia and reperfusion) on systemic 
vascular function. Improvement in vascular function as a consequence of repeated IPC may 
contribute to a reduction in the risk of future ischaemic events. Hence, RIPC may be of direct 
benefit in terms of reducing the impact of infarction on affected cardiac muscle, but also 
reducing the likelihood of atherothrombotic events occurring in the first instance by virtue of 
this impact on endothelial and vascular function. Importantly, very few studies have 
evaluated the effects of RIPC on the cerebrovascular system in terms of function, protection 
against cerebral ischaemia and/or prevention against cerebrovascular dysfunction. This 
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literature review will provide a brief overview of the research studies to date investigating the 
impact of RIPC on the cardio and cerebro- vascular systems. 
 
1.2. Ischaemic Preconditioning  
Murry et al. introduced the potential cardioprotective benefits of an episode of IPC (Murry et 
al., 1986). In this study, the IPC protocol involved occlusion of the left anterior descending 
artery of dogs 4 times (for 5-minutes per occlusion), alternated with 5-minutes of reperfusion. 
This was followed by 40-minute ischaemia of the same artery. A 75% smaller infarction size 
was evident after IPC, compared to control animals that underwent a sham-intervention. This 
finding provided experimental support for clinical observations in the mid-1980s, which 
suggested that post-myocardial infarction patients with a prior history of angina (i.e. 
myocardial ischaemia) demonstrated better ejection fraction (Matsuda et al., 1984). These 
data contributed to the concept that exposure to (non-lethal) cardiac ischaemia in the period 
preceding coronary ischaemia may protect against the impact of reperfusion of the occluded 
artery on the magnitude of myocardial damage. Subsequent studies provided further clinical 
evidence that “pre-conditioning” of the myocardium before an acute myocardial infarction, 
for example through prodromal angina, leads to a smaller infarct size (Ottani et al., 1995) and 
improves (in-hospital) outcome (Kloner et al., 1995, Nakagawa et al., 1995). 
Despite these intriguing observations, direct clinical application of IPC is challenging and 
associated with some limitations. Compared to control groups undergoing traditional 
coronary artery bypass surgery (CABG), smaller post-surgery release of cardiac troponins 
was observed after IPC applied to human coronary arteries preceding CABG (Jenkins et al., 
1997), along with attenuated impairment in cardiac function (Wu et al., 2000). Nevertheless, 
the direct application of IPC to coronary vessels can only be applied to planned ischaemic 




1.2.1. Remote IPC and the Heart 
Przyklenk and colleagues performed a landmark study in 1993, in which they demonstrated 
that cyclical ischaemia and reperfusion of the circumflex coronary artery was associated with 
protection of cardiac territory supplied by the left anterior descending artery (i.e. an area 
remote from the distribution of the circumflex coronary artery) (Przyklenk et al., 1993). They 
provided support for the notion that IPC can afford infarct-sparing protection for distinct 
areas within the heart; and initiated several investigations to explore the potential effects of 
remote IPC (RIPC). 
Preclinical studies exploring the effects of RIPC have typically collected perfusate from 
ischaemic preconditioned tissue/animals and subsequently perfused naïve hearts using a 
Langendorff preparation. Interestingly, several studies have demonstrated that infarct sizes 
were significantly smaller in both donor hearts subjected to RIPC and the naïve recipient 
hearts that received the perfusate from a pre-conditioned donor (Huffman et al., 2008, 
Dickson et al., 1999). This demonstrates the ability of RIPC to reduce damage upon 
ischaemic injury in remote areas, possibly through a blood-borne pathway. Although the 
underlying protective mechanisms may differ, the efficacy of RIPC and IPC seem 
comparable. Furthermore, evidence is present for between-species protection of RIPC, since 
rabbit hearts demonstrated protection against prolonged ischaemia when perfused with 
human preconditioned serum (Michelsen et al., 2012, Shimizu et al., 2009). This suggests a 
similarity in the factor/s conferring protection across species, and that such agent/s remain 
conserved during such procedures, allowing binding to the recipient receptors. 
Experimental observations on the impact of RIPC have been supported by clinical studies 
demonstrating the potential of RIPC to prevent or attenuate (ischaemia-induced) tissue 
15 
 
damage in the heart and various other organs (e.g. liver, brain, vascular endothelium and 
skeletal muscle) (Yoshizumi et al., 1998, Stenzel-Poore et al., 2003, Pang et al., 1995, Jabs et 
al., 2010). Kharbanda et al. used a swine model of RIPC of the limb (using a blood pressure 
cuff) and evoked reduction in the magnitude of myocardial damage against prolonged 
ischaemia (Kharbanda et al., 2002).  
Studies have typically explored clinical effects by applying an episode of cyclical RIPC on a 
limb using a blood pressure cuff, before (planned) prolonged myocardial ischaemia. Several 
studies have examined the impact of RIPC in patients undergoing impending CABG or 
percutaneous coronary interventions (PCI), as these strategies induce global myocardial 
ischaemia (and subsequently cardiac damage) as reflected by a post-surgery elevation in 
cardiac troponins. Accordingly, strategies that can attenuate the global myocardial ischaemia 
have clinical relevance. Most of these studies reported lower peri-/post-operative levels of 
troponins in patients undergoing CABG and elective PCI (Heusch, 2013), findings reflected 
by meta-analyses (D'Ascenzo et al., 2012, Brevoord et al., 2012). More importantly, RIPC 
may reduce peri-operative myocardial infarction (Brevoord et al., 2012, Thielmann et al., 
2013) as well as post-operative atrial fibrillation (Candilio et al., 2015). For example, 
Thielmann and co-workers demonstrated in 329 patients undergoing CABG that preceding 
RIPC reduced post-CABG troponin levels, and also lowered all-cause mortality following 
1.5-years follow-up (Thielmann et al., 2013). RIPC may therefore possess potential long-term 
clinical benefit in humans. 
 
Instituting RIPC before prolonged ischaemia does not seem to be a pre-requisite for 
cardioprotection, since RIPC, applied to the lower limbs of pigs during cardiac ischaemia, 
was also associated with reduced severity of myocardial infarction and improved indices of 
cardiac function (Schmidt et al., 2007). In 2010, Bøtker and colleagues explored this concept 
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in humans by randomising patients with suspected acute myocardial infarction to RIPC or a 
control intervention during transport to the hospital for primary PCI (Botker et al., 2010). 
They found that RIPC before hospital admission was associated with better myocardial 
salvage, measured by myocardial perfusion imaging. A follow-up study of this patient 
population indicated that, after a median follow-up of 3.8 years, the RIPC-treated patients 
experienced fewer major adverse cardiac and cerebrovascular events (Sloth et al., 2014). The 
potential of RIPC to improve outcomes in patients with acute myocardial infarction 
undergoing primary PCI was supported by subsequent studies (Munk et al., 2010, Rentoukas 
et al., 2010). 
 
1.2.2. Remote IPC and the Vasculature  
There is also evidence to suggest that (R)IPC can have a direct impact on the vasculature. 
Studies have been performed on large conduit and small microvessels including the 
cutaneous vasculature. One study, using RIPC applied to the upper arm, measured tissue 
oxygen saturation and capillary blood flow (by means of laser Doppler) in the thigh and 
observed an increase in both while the RIPC procedure was being performed (Kraemer et al., 
2011). More recently it has been shown that RIPC applied to the upper arm of patients who 
have recently undergone a tissue transfer operation improved blood flow (laser Doppler) and 
tissue oxygen saturation, aiding the recovery of the transferred tissue (Kolbenschlag et al., 
2016). Taken together, research is now strongly suggesting that an acute bout of RIPC can 
improve blood flow in peripheral and cutaneous vessels as well as the myocardium.      
 
The effects of RIPC within the vasculature have not been limited to changes in blood flow. 
Changes in endothelial function have been observed, with significantly improved brachial 
artery flow mediated dilation (FMD) following RIPC (Moro et al., 2011). Remarkably, this 
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improvement in FMD was detected both when the IPC was applied to the same arm that was 
used for FMD assessment, but also when the stimulus was applied to the upper thigh (RIPC) 
(Moro et al., 2011). In contrast, Loukogeorgakis et al. (2005) reported no effect of RIPC on 
brachial artery FMD when RIPC was applied to the contralateral arm, along with no change 
in resting blood flow. This finding was further supported by both van den Munckhof et al. 
(2013) and Seeger et al. (2016) when it was reported there was no difference in FMD % 
change, nor brachial artery diameter when  FMD was performed post IPC compared to 
SHAM. Similarly, response to increased acetylcholine was found to be unchanged following 
a bout of RIPC (Kharbanda et al., 2002).  
Whilst it is not possible to induce an ischaemia-reperfusion injury (IRI) within a human 
myocardium, it is possible to induce a non-lethal IRI to human conduit peripheral arteries by 
means of causing reversible endothelial dysfunction using a blood pressure cuff inflated to a 
supra-systolic pressure for 20 minutes. Previous research studies have shown that RIPC can 
attenuate the dysfunction caused by IRI’s with Kharbanda et al identifying that IPC applied 
before a 20 minute forearm occlusion significantly reduced the endothelial dysfunction 
measured via FMD compared to controls (Kharbanda et al., 2001). This protection against 
endothelial dysfunction was further supported in a study by Loukogeorgakis et al. (2005). 
Interestingly, the RIPC effect on IRI may be age dependent. Attenuation of endothelial 
dysfunction measured by FMD, induced by a 15 minute brachial artery occlusion (IRI) was 
reported in younger individuals (20-25 yr), but this protection was not detected in older 
individuals (68-77 yr) (van den Munckhof et al., 2013). More recently it was found that 
patients with heart failure showed an exaggerated decline in endothelial function during an 
IRI compared to healthy controls and that RIPC does not reduce the endothelial dysfunction 
caused by an IRI within heart failure patients but does in healthy individuals despite no 
differences in baseline FMD between RIPC and SHAM conditions (Seeger et al., 2016). The 
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lack of response to the RIPC stimulus within the heart failure patients was believed to be 
largely as a result of this exaggerated decrease in endothelial function compared to healthy 
controls, which RIPC was simply not able to attenuate.   
 
1.2.3. Remote IPC and the Brain 
Whilst the beneficial effects of (R)IPC on the cardiovascular system has been extensively 
researched, its effect on the cerebrovascular system has received less attention. Nevertheless, 
there is a growing body of animal research that supports the notion that RIPC provides 
protection against ischaemic injuries in the cerebrovascular system and provides 
neuroprotection. This is of enormous clinical relevance as brain ischaemia is one of the 
leading causes of morbidity and mortality in the world (Liu et al., 2009).  
Hoyte et al., (2006) conducted a study in mice and employed 15 minutes of middle cerebral 
artery (MCA) occlusion 72 hours prior to inducing a 45-minute injurious cerebral ischemia. 
They reported an increase in regional brain blood flow during the injurious occlusion, 
measured via magnetic resonance perfusion and laser Doppler flowmetry, in the mice that 
received the IPC as well as a reduction in infarct size (Hoyte et al., 2006). Ren and colleagues 
extended this work by applying RIPC to the left femoral artery of rodents, 2 days prior to 
inducing cerebral ischaemia. They found that RIPC was associated with a reduction in 
infarction size compared to the animals with no preconditioning (Ren et al., 2008). 
Interestingly, Ren et al identified that an IPC protocol of 2 x 15 minutes of occlusion-
reperfusion generated strong protection, whilst 2 x 5 minutes of occlusion-reperfusion did not 
provide protect against ischaemic injury. Taken together this data provides evidence that 
RIPC can offer cerebrovascular protection against cerebral ischaemia, with some suggestion 
that longer periods of ischaemia confer a stronger protective effect. Jensen and colleagues 
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also observed that pigs who received RIPC to the limb, displayed an accelerated recovery in 
neurological function and  ECG pattern and demonstrated a lower brain lactate concentration 
compared to controls following ischaemic injury as a result of hypothermic circulatory arrest 
(Jensen et al., 2011).  Taken together, these data provide evidence that (R)IPC can offer 
cerebrovascular and neural protection against cerebral ischaemia. Nevertheless, research 
work in humans is warranted to be able to translate this into clinical practice. 
Research examining the impact of repeated RIPC on cerebrovascular function and clinical 
outcomes in humans is limited. Two large scale clinical trials have been conducted examining 
the potential benefits of repeated RIPC on human cerebrovascular function in patients with 
intracranial arterial stenosis (IAS). The studies employed bilateral limb RIPC twice daily for 
300 days and found a significant reduction in stroke recurrence along with a significant 
increase in cerebral perfusion (Meng et al., 2012). Remarkably, the same group more recently 
observed a significant reduction in ischaemic events following a course of 180 days of 
bilateral limb IPC, twice daily, applied within an older population of IAS patients, with no 
adverse changes to heart rate or arterial blood pressure (Meng et al., 2015). Whilst these 
studies provide indirect evidence that RIPC may have an impact on cerebrovascular function 
in humans, no study to date has directly assessed this concept.  
 
1.3. The Cerebrovasculature 
The next section of this literature review will outline how to assess cerebral blood flow non-




1.3.1. Anatomy of the Cerebral Vasculature  
Blood flow to the brain is supplied via two large extra-cranial arteries bilaterally; the internal 
carotid (ICA) and vertebral arteries (VA). The ICA bifurcates from the common carotid 
artery whilst the vertebral arteries originate from the subclavian arteries and join to form the 
basilar artery.  These arteries rise to form the anterior and posterior components of the circle 
of Willis, an anastomotic ring at the base of the brain. The ICA continues upwards to the base 
of the brain to form the anterior and middle (MCA) cerebral arteries bilaterally (Cipolla 
2009), whilst the basilar artery bifurcates to eventually form the posterior cerebral arteries. 
These three primary intracranial arteries are all connected via communicating arteries 
(Boyajian et al., 1995). The anterior cerebral artery supplies the frontal lobe of the brain 
whilst the MCA, the largest branch of the internal carotid artery, supplies blood to a small 
portion of the frontal lobe as well the lateral face of the temporal and parietal lobes. Finally, 
the posterior cerebral artery extends laterally before turning in a posterior direction to deliver 
blood to the hindbrain (occipital lobe, cerebellum ,medulla oblongata) (Willie et al., 2011).  
These three main arteries that branch from the circle of Willis continue to progressively split 
into smaller arteries and arterioles (e.g. pial vessels) that run along the surface of the brain 
until they ultimately penetrate the tissue in order to supply blood to the brain (Cipolla 2009). 
 
1.3.2. Measurement of Cerebral Blood Flow 
The ability to measure CBF can provide valuable information on the functional status of the 
blood vessels that supply the brain, which is of obvious importance to clinicians and 
researchers. Nevertheless, assessing CBF is difficult due to the brain being enclosed by the 
cranium, which limits the effectiveness of non-invasive imaging techniques. Transcranial 
Doppler (TCD) ultrasound has become the most commonly utilised method to examine CBF 
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in humans (Purkayastha and Sorond, 2012). The following section provides an overview of 
the use of TCD for the measurement of CBF.   
 
1.3.2.1. Transcranial Doppler (TCD) 
Transcranial Doppler was first introduced in 1982 by Aaslid and colleagues and offers a safe, 
non-invasive, non-ionising, portable and inexpensive method for the assessment of CBF 
using a pulsed Doppler transducer (Aaslid et al., 1982) (Sarkar et al., 2007). TCD offers three 
windows for the assessment of intra cranial blood flow; (i) orbital (ii) temporal (iii) foramen 
magnum. Unlike Duplex ultrasound that offers a B mode image, TCD can be described as a 
‘blind’ technique as the vessels cannot be visualised, and identification of vessels is 
established via; the window used, position of the probe, depth of the ultrasonic beam, and the 
values and shape of the velocity waveforms (Sarkar et al., 2007). 
 
TCD ultrasonography uses probes that emit ultrasonic beams that can be focused onto vessels 
of interest. The assessment of cerebral blood velocity is derived from the Doppler shift, 
created by the reflection of ultrasound waves from moving erythrocytes (red blood cells) 
within the blood vessel that are returned to the receiver unit in the Doppler probe. Simply, the 
Doppler shift refers to the difference between the transmitted and received ultrasound signals 
(Aaslid, 1986), with faster erythrocyte movement associated with higher velocities, and by 
extension, blood flow. 
 
The relative success and accuracy of a TCD sonography scan depends heavily on two main 
factors; (i) the sonographer’s technical ability and (ii) the sonographer’s anatomical and 
spatial knowledge of the cerebral vasculature. Knowledge of typical vessel depths, correct 
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directions and mean blood flow velocities all affect the chances of collecting valid cerebral 
measurements (Arnolds and von Reutern, 1986) (Table 1.1). 
 
Table 1-1: Typical patterns for identification of cerebral arteries 
Artery Window Depth (mm) Direction Mean Flow Velocity 
MCA Temporal 30 to 60 Toward probe 55 ± 12 cm/s 
ACA Temporal 60 to 85 Away 50 ± 11 cm/s 
PCA Temporal 60 to 70 Bidirectional 40 ± 10 cm/s 
Abbreviations: MCA, middle cerebral artery; ACA, anterior cerebral artery, PCA, posterior 
cerebral artery.  
 
1.3.3. Cerebrovascular Control and Regulation  
In order to maintain normal functioning, the brain requires a constant adequate nutritional 
flow due to its high metabolic demand. In resting conditions the brain is accountable for 
approximately 25% of total oxygen (O2) consumption and receives 15-20% of total cardiac 
output (Q) (Franco Folino, 2007). Despite the high metabolic demand, the brain has a very 
limited ability to store energy, therefore CBF needs to be highly regulated in order to 
maintain a constant supply of nutrients and O2 (Peters et al., 2004). The main regulatory 
features of the cerebral circulation applicable to this thesis are detailed below. 
 
1.3.3.1. Cerebral autoregulation 
Autoregulation of CBF refers to the brain’s ability to maintain a relatively constant blood 
flow despite changes in arterial blood pressure (BP). A rapid and unopposed drop in BP, and 
subsequently CBF, can lead to dizziness and fainting. Alternatively, a similarly rapid rise in 
BP and CBF can lead to increased mechanical stress on the smaller fragile cerebral blood 
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vessels, which can be fatal. Indeed, evidence shows that brain injury occurs when 
autoregulatory mechanisms are lost (Euser and Cipolla, 2007, Novak et al., 1998). 
It was traditionally believed that cerebral autoregulation allowed for CBF to remain entirely 
constant within certain high-low limits of blood pressure (Bayliss et al., 1895, Franco Folino, 
2007, van Beek et al., 2008). Nonetheless, recent studies have shown that such a tight 
regulation, and across such a large range, is not strictly accurate. 
The mechanisms involved in the intrinsic proficiency of cerebral vessels to maintain a 
constant CBF over a range of systemic BP levels is yet to be fully elucidated, yet most likely 
involves myogenic and/or autonomic mechanisms (Paulson et al., 1990, Aries et al., 2010, 
Strandgaard and Paulson, 1984). The myogenic reflex is the intrinsic ability of the vascular 
smooth muscle to respond to changes in pressure or mechanical load, with a constriction in 
response to increased pressure and dilation in response to decreases in pressure, referred to as 
the ‘Bayliss effect’ (Mellander, 1989). The cerebral vessels are also heavily innervated by 
neural sympathetic fibres that has also been shown to be involved in the autoregulatory 
responses. Whilst transient changes in arterial BP occur throughout the cerebrovasculature as 
well as within extra-cranial vessels, the pial arterioles appear to be the most responsive to 
these changes (Willie et al., 2014). 
 
1.3.3.2. Measurement of Cerebral Autoregulation 
The assessment of cerebral autoregulation requires changes in arterial BP that induces 
transient alterations in CBF. Whilst there is no ‘gold standard’ method available for the 
assessment of cerebral autoregulation (Panerai, 1998), a number of techniques have been 
previously used to achieve these rapid fluctuations in BP. Traditionally, sudden deflation of 
bilateral thigh cuffs after a period of inflation to supra-systolic levels was used to induce 
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transient decreases in BP (Sorond et al., 2009), however this technique is associated with 
high levels of discomfort as well as a variability in the levels of BP change with each cuff 
deflation. More recently, a simple squat to stand procedure has been found to produce 
transient changes in BP, yet with less discomfort than the traditional bilateral thigh cuffs 
(Lipsitz et al., 2000). Work by Serrador et al. (2005) identified that the sit to stand procedure 
could be successfully performed by elderly patients and the results were similar to that 
produced by the thigh cuff deflation technique. Additionally, Sorond and colleagues 
established that the sit to stand protocol was better tolerated and the CBF response was larger 
compared to the thigh-cuff technique (Sorond et al., 2009).  
 
1.3.3.3. Arterial blood gases 
The cerebrovasculature is also highly sensitive to changes in blood gas content, particularly 
the partial pressure of carbon dioxide (PaCO2) (Brian et al., 1996). Kety and Schmidt (1948) 
were the first to document the effect of CO2 on CBF, outlining that inhalation of 5% CO2 mix 
increased CBF by 50% in humans and that a 7% CO2 mix increased CBF by 100%. This 
response in CBF to changes in PaCO2 is referred to as cerebrovascular CO2 reactivity, which 
acts as a crucial homeostatic function aiding the maintenance and regulation of central pH, 
affecting the respiratory central chemoreceptor stimulus (Ainslie and Duffin, 2009). The most 
common method of tracking arterial CO2 levels is via the measurement of the partial pressure 
of end-tidal CO2 in exhaled air (PETCO2). Typical resting end tidal CO2 values in humans are 
between 35-40 mmHg.  The sensitivity of the cerebrovasculature to CO2 is highlighted by 
recent studies showing a 1 mmHg change in PETCO2 can alter CBF by up to 4-6% (Regan et 
al., 2013).  It is now known that increases in arterial CO2 cause a relaxation of the vascular 
smooth muscles in cerebral vessels, with the smaller cerebral vessels being the most sensitive 
to these changes resulting in a greater response. A number of potential mechanisms involved 
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in the vasodilation response to hypercapnia (a state of increased levels of CO2 in the blood) 
have been suggested, however are yet to be fully elucidated. One of these mechanisms 
involves changes in pH as a result of increased CO2, which may activate K
+ 
channels in the 
vascular smooth muscle and stimulate relaxation of cerebral vessels (Kitazono et al., 1995, 
Jackson, 2005). Additionally, evidence is suggesting a role of nitric oxide (NO) in the 
vasodilation response to hypercapnia (Toda et al., 2009) with previous work showing that the 
dilatory response of cerebral vessels during hypercapnia is attenuated when a NO synthase 
inhibitor was used (Smith et al., 1997, Schmetterer et al., 1997)   
 
Whilst cerebral blood vessels are also sensitive to changes in Oxygen (O2), the range in 
which this sensitivity is different to CO2. Whilst small changes in CO2 cause significant 
changes in CBF, significant changes as a result of O2 occur when stretched further than 
normal values. The increase in CBF as a result of hypoxia occurs via direct effects on 
vascular cells of cerebral arteries and arterioles. When in a hypoxic state, this induces 
reductions in ATP levels and opens KATP  within the vascular smooth muscle, resulting in 
both a hyperpolarization and vasodilation on cerebral vessels (Tomiyama et al., 1999). 
 
1.3.3.4. Measurement of Carbon Dioxide Reactivity 
Measuring the cerebrovascular response to changes in CO2 concentration reflects an index of 
the ability of the cerebrovascular beds to dilate or constrict (Ainslie and Duffin, 2009). With 
the use of TCD, a significant amount of previous research has evaluated cerebrovascular 
reactivity in healthy individuals but also in clinical settings, such as patients with heart failure, 
head trauma, hypertension and following strokes (Puppo et al., 2008, Maeda et al., 1994, 
Wijnhoud et al., 2006). Relationships between cerebrovascular CO2 reactivity and systemic 
endothelial function have been discovered, suggesting an increased CO2 reactivity response is 
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positively associated with all-cause mortality and decreased cerebrovascular risk (Lavi et al., 
2006, Ainslie et al., 2007b).  
 
CO2 reactivity can be assessed in three potential ways. The earliest technique used was 
breath-holding, whereby participants would hold their breath in order to progressively 
increase CO2. This technique has many limitations. Individual variability between individuals 
in many factors such as; metabolic, size of lungs, age all affected the CBF response to breath 
holding (Fierstra et al., 2013). Following this, the rebreathing of exhaled gas became, and 
remains, a common technique to achieve increases in PETCO2. This method requires minimal 
equipment with just an exhaled gas reservoir and gas sensors necessary and allows 
assessment of ventilatory response. Nevertheless, this method does have limitations, 
rebreathing of exhaled gas causes a ramp-like response with each breath causing an increase 
in PETCO2, therefore not allowing a stable measurement of increased CBF. Thirdly, 
researchers have adopted the use of external CO2 supplied to a participant by means of a non-
rebreathing face mask, with inspired CO2 concentrations ranging from 2-7% (Fierstra et al., 
2013). This method is favourable as it can induce a standardised hypercapnic stimulus 
(Vernieri et al., 2004).   
 
1.4. Summary 
This literature review has sought to provide a historical perspective around the concept of 
ischaemic preconditioning from animal to human models, and aimed to highlight the 
evidence that shows RIPC has beneficial effects on both the heart and peripheral blood 
vessels in humans. The (R)IPC induced mechanisms responsible for these beneficial 
adaptations are poorly understood and beyond the scope of this review (Heusch et al., 2015). 
Importantly, whilst animal studies have shown that RIPC can improve aspects of 
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cerebrovascular function and improve neural recovery from ischaemia, very little is known 
about its effect on the human cerebrovascular system. Two clinical trials have revealed that 
RIPC reduces stroke recurrence, suggesting that it may affect cerebral blood flow and/or 
function, yet no study has examined this in healthy humans to date.  
Therefore, the aims of this thesis were to assess the impact of 40 minutes of bilateral arm IPC, 
or SHAM, on both CO2 reactivity, cerebral autoregulation and its effect on a hypercapnia-
induced dysfunction of cerebral autoregulation. It was hypothesised that an acute bout of 
RIPC would enhance CO2 reactivity and cerebral autoregulation, and that RIPC would also 
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Ischaemic Preconditioning (IPC) is characterised by brief cycles of ischaemia followed by 
reperfusion, and has been shown to have cardioprotective effects beyond the vascular bed 
directly exposed to the IPC stimulus, known as remote (R)IPC (Jones et al., 2014, Przyklenk 
et al., 1993, Kharbanda et al., 2002). These protective effects attained from RIPC have been 
demonstrated in both animal and human models, and have typically focused on the heart. 
Nevertheless, there is accumulating evidence showing that RIPC offers protection to other 
vascular beds and organs (Koch and Gonzalez, 2013, Jensen et al., 2011). 
One of these areas that may also benefit from RIPC relates to the brain. Research 
investigating the acute impact of RIPC on the brain is limited to animal models, which have 
indicated that IPC has neuroprotective effects (Jensen et al., 2011). Hoyte et al reinforced 
these findings, by conducting a study in mice and employing 15 minutes of MCA occlusion 
72 hours prior to inducing cerebral ischaemia. They reported an increase in regional brain 
blood flow following the ischaemic injury, measured via magnetic resonance perfusion and 
laser Doppler flowmetry, in the mice that received the RIPC as well as a reduction in infarct 
size (Hoyte et al., 2006). Ren and colleagues extended these findings to a RIPC model by 
applying RIPC to the left femoral artery of rodents, 2 days prior to inducing cerebral 
ischaemia. It was observed that RIPC caused a reduction in infarction size compared to the 
animals with no preconditioning (Ren et al., 2008). Interestingly, Ren et al identified that the 
dosage of RIPC has an effect on the protection attained with an RIPC protocol of 2 x 15 
minutes of occlusion-reperfusion generated strong protection, whilst 2 x 5 minutes of did not 
provide protection against ischaemic injury. Taken together this data provides evidence that 




The only study to date in humans, involving stroke survivors, supports the general notion that 
RIPC has neuroprotective effects. Meng et al., (2012) employed daily RIPC for 300 days and 
found improved cerebral perfusion, faster recovery and a 70% lower stroke recurrence 
compared to standard care (Meng et al., 2012). Despite these observations, no previous study 
has directly explored the impact of RIPC on cerebrovascular function, and the ability to 
reduce or prevent the impact of potentially harmful stimuli on the cerebrovascular circulation 
in humans in vivo.  
 
The typical approach to test if RIPC can protect against ischaemia in vivo in humans is to 
induce vascular endothelial dysfunction via ischaemia reperfusion injury. When applied to 
the forearm, this involves using a blood pressure cuff inflated to a supra-systolic pressure on 
the upper arm for 20 mins, followed by 20 mins of reperfusion (van den Munckhof et al., 
2013). Such procedures are impractical to induce cerebrovascular ischaemia-reperfusion 
injury. Previous studies have suggested that a sustained period of hypercapnia (inhalation of 
higher levels of carbon dioxide) transiently impairs cerebral autoregulation (Birch et al., 1995, 
Zhang et al., 1998), and thus cerebrovascular function. The aim of the current study, therefore 
was to independently assess the impact of 40 mins of bilateral arm IPC, or SHAM, on CO2 
reactivity, cerebral autoregulation and finally on the effect of hypercapnia-induced 
dysfunction of cerebral autoregulation. It was hypothesised that RIPC would i) enhance CO2 
reactivity and cerebral autoregulation and ii) attenuate the hypercapnia-induced dysfunction 
in cerebral autoregulation, compared to SHAM. This study would i) demonstrate the potential 
impact of RIPC on the cerebrovasculature, and ii) introduce hypercapnia as a potential 





Ten participants (8 males and 2 females, Table 2.1) were recruited for the study.  Participants 
were recreationally active, engaging in low to moderate intensity exercise 2-3 days per week. 
Smokers and individuals with a history of cardiovascular diseases, including diabetes, 
hypertension or hypercholesterolemia were excluded. Participants were informed of the study 
protocol verbally and in writing before providing written informed consent. The study was 
approved by the Liverpool John Moores University ethics committee and adhered to the 
standards set out in the Declaration of Helsinki (2000).  
 
Table 2-1: Descriptive characteristics of participants. 
Characteristics Group 
Age (years) 32.6 ± 11.1 
Height (cm) 176.5 ± 6.6 
Weight (kg) 81.0 ± 17.3 
BMI (kg/m
2
) 25.9 ± 4.4 
Systolic Blood Pressure (mmHg) 125 ± 10 
Diastolic Blood Pressure (mmHg) 61 ± 5 
Mean Arterial Pressure (mmHg) 85 ± 7 
 
2.2.2. Research Design 
Participants were required to attend two laboratory visits (separated by a minimum of 3 days), 
that were performed at the same time of day in order to control for diurnal variation in 
cerebrovascular function (Ainslie et al., 2007a). All participants arrived for testing following 
an overnight fast and were asked to refrain from alcohol and exercise for 24h and caffeine for 
12h before each visit. Visits were randomised and counterbalanced to receive either the 
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bilateral upper arm RIPC or SHAM condition. Each visit consisted of the bilateral assessment 
of middle cerebral artery blood flow velocity (MCAv) during RIPC or SHAM. Following a 5 
min seated rest period, cerebral autoregulation was assessed using a 5 min squat-stand 
protocol and a 5 min seated rest period followed by 9 mins of hypercapnia, 4 mins whilst 
seated, followed by 5 mins of cerebral autoregulation, as above (see Figure 2.1).  
 
Figure 2.1: Schematic of research design 
 
2.2.3. Measurements   
2.2.3.1. Remote Ischaemic Preconditioning and Sham 
The RIPC condition consisted of 8 bouts in total involving the inflation of a blood pressure 
cuff on the upper arm using a rapid inflator (EC-20; D.E Hokanson) to 220 mmHg for 5 
minutes.  Cuffs were placed bilaterally however were independently inflated, after which the 
cuff on the contralateral arm was inflated.  This allowed for a 5 minute period of reperfusion 
for each arm. The SHAM condition consisted of an identical protocol, however with the 
difference that the cuff was inflated to a pressure of 10 mmHg.  
 
2.2.3.2. Middle Cerebral Artery Velocity  
Following 10 minutes rest in the supine position, MCAv was continuously measured through 
the temporal window using transcranial Doppler ultrasonography (TCD). A 2-MHz Doppler 
probe (Spencer Technologies, Seattle WA, USA) was adjusted until an optimal signal was 
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identified, as described in detail previously (Willie et al., 2011), and held in place using a 
Marc 600 head frame (Spencer Technologies, Seattle, USA) to prevent subtle movement of 
the Doppler probe and maintain insonation angle accuracy. Once the optimal MCA signal 
was attained in the temporal window, the probe location and machine settings (depth, gain 
and power) were recorded to identify the same imaging site for both assessments. MCAv was 
measured bilaterally and the signal that was free of noise or artefact was selected for analysis. 
Participants were instrumented with a two-way valve-breathing (MLA1028, ADInstruments, 
Colorado Springs, Colorado, USA) mouthpiece (MLA1026, ADInstruments) from which end 
tidal CO2 (PETCO2) was measured using a calibrated gas analyser (ML206, ADInstruments). 
Continuous beat-by-beat blood pressure was obtained from a digit (Finapres, Amsterdam, 
Netherlands) and heart rate acquired from a 3 lead electrocardiogram (Powerlab, AD 
Instruments, Oxford, UK). An index of cerebrovascular resistance (CBVC) was calculated 
using the ratio of MCAv to mean arterial pressure (MAP). All data was sampled at 50 Hz 
with a data acquisition system (PowerLab, ADInstruments, Oxford UK) and displayed on 
LabChart (ADInstruments, Colorado Springs, Colorado, USA).  
 
2.2.3.3. Cerebral Autoregulation  
Changes in blood pressure and MCAv was assessed using a squat to stand procedure in order 
to induce transient changes in arterial blood pressure. Participants replicated the experimenter 
whilst performing these manoeuvres. Participants performed two sets of squat-stand 
manoeuvres at 0.10 Hz (5 second squat- 5 second stand) whilst breathing normal atmospheric 
air, and again whilst breathing a gas concentration of 5% CO2. The first set of squat stands 
was preceded by a 5-min of seated rest period. The second set of squat stands followed 4 
minutes of hypercapnia, and the order of squats (normal air – 5% CO2) was counterbalanced. 
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When the squat-stand with 5% CO2 mix was performed first, it was ensured that PETCO2 had 
returned to baseline values before commencing the second set of squats.  
2.2.3.4. Hypercapnia 
A period of 2 minutes of baseline breathing of normal room air was followed by 4 minutes 
inhalation of a 5% CO2, 21% oxygen and nitrogen balance mix from a Douglas bag in order 
to induce temporary cerebral dysfunction whilst sat in a rested seated position. Cerebral CO2 
reactivity was taken from the final 30 seconds of the 4 minutes of hypercapnia.  
 
2.2.4. Data Reduction 
Data was extracted from LabChart averaged over 5 minutes periods prior to and during RIPC 
or SHAM. Averages of variables were also extracted during each phase of the protocol (e.g. 
average during 4 mins hypercapnia and 5 min squat-stands). For CO2 reactivity an average of 
3 mins resting baseline and the last 30 secs of the 4 min period of hypercapnia were used. 
The reactivity was estimated by calculating the slope of the line between increases in MCAv 
and PETCO2 using linear regression analysis. Data collected from the squat- stands was 
extracted from LabChart every 0.1 seconds across the 5 minute period. Specifically, MCAv, 
PETCO2, MAP were the variables used for transfer function analysis.     
 
The relationship between changes in MCAv and arterial BP was assessed via the transfer 
function analysis in accordance with standardised guidelines (Claassen et al., 2016). Transfer 
function analysis was performed using MATLAB (2010b; MathWorks-Inc., Natick, MA) in 
order to calculate associated power (gain) and timing (phases) over three different 
frequencies; very low (0.02 – 0.07 Hz), low (0.07 – 0.20 Hz) and high (0.20 – 0.50 Hz) 
(Claassen et al., 2016). Transfer function also produces an estimated reliability of the 




2.2.5. Statistical Analysis 
A two factor (intervention*time) general linear model was employed to analyse resting 
MCAv and MAP during the RIPC and SHAM protocol. Similarly, a two factor 
(intervention*time) general linear model was employed to analyse variables in response to 
hypercapnia and squat-stands. Statistically significant interactions were followed up with the 
least significant difference (LSD) approach to multiple comparisons. A paired sample t-test 
was used to analyse averaged variables during hypercapnia and squat-stands, the relative 
change in MCAv, PETCO2, MAP during hypercapnia and the reactivity slopes between 
MCAv and PETCO2. Analysis was conducted using Statistical Package for Social Sciences 
(Version 17; SPSS Inc., Chicago, IL). Statistical significance was delimited at P<0.05 and 
exact P values are cited (P values of “0.000” provided by the statistics package are reported 







2.3.1. Exposure to RIPC or SHAM  
MCAv did not change throughout either the 40 min RIPC or SHAM, with no significant main 
effect for time (P=0.728), condition (P=0.958) or interaction between condition*time 
(P=0.463, Figure 2.2). A significant main effect for time (P=0.016) was evident for MAP 
across the RIPC and SHAM conditions with MAP increasing 5 mmHg (95% CI: 84, 92) over 
the 40 min period.  There was no main effect for condition (P=0.825), or condition*time 
interaction (P=0.762, Figure 2.2).    
 
Figure 2.2: Middle cerebral artery velocity (MCAv) and mean arterial blood pressure (MAP) 





2.3.2. Cardiorespiratory variables measured throughout each cerebrovascular 
assessment  
MAP was significantly higher in the SHAM condition (106 mmHg) during hypercapnia 
compared RIPC (101 mmHg) (P=0.027, 95% CI:  9.58, 0.76 mmHg). There was no 
significant difference between conditions for any other cardiorespiratory measurements taken 







Table 2-2: Cardiorespiratory variables measured throughout each cerebrovascular assessment in RIPC and SHAM. 
 
REST Cerebral Autoregulation Hypercapnia 
Hypercapnic Cerebral 
Autoregulation 
 RIPC SHAM  P Value RIPC SHAM  P Value RIPC SHAM P Value RIPC SHAM P Value 
MAP 
(mmHg) 
85 ± 7 85 ± 4 0.925 99 ± 5 98 ± 8 0.847 101 ± 5 106 ± 6 0.027 109 ± 6 110 ± 7 0.720 
HR 
(bpm) 







59 ± 12 0.586 61 ± 11 58 ± 8 0.251 77 ± 11 79 ± 15 0.763 83 ± 13 81 ± 13 0.530 




















16 ± 3 16 ± 3 0.370 19 ± 3 19 ± 3 0.401 20 ± 4 19± 3 0.771 23 ± 4 23 ± 6 0.602 
Abbreviations: MAP, Mean Arterial Pressure; HR, Heart Rate; PETCO2, Partial Pressure Carbon Dioxide; CBVR, Cerebrovascular 
Conductance; Fb, Frequency of Breathes
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2.3.3. Effect of RIPC or SHAM on CO2 reactivity  
 
Figure 2.3:  An example recording from one representative individual of middle cerebral 
artery velocity (MCAv), mean arterial pressure (MAP) and end-tidal pressure of carbon 
dioxide (PETCO2) at baseline and during hypercapnia. 
 
MCAv increased by 18 cm/s (95%CI: 54, 66) during hypercapnia following both the RIPC 
and SHAM conditions (Figure 2.4), as evidenced by a significant main effect for time 
(P<0.001).  There was no difference in MCAv increases to hypercapnia between conditions 




Figure 2.4: Middle cerebral artery velocity (MCAv) when breathing normal air and 5% CO2 












The relative increase in MCAv during hypercapnia when expressed as a relative change from 
baseline was not different between conditions (P=0.365: Figure 2.5). Similarly, the relative 








Figure 2.5: Percentage (%) change in middle cerebral artery velocity (MCAv), partial 
pressure carbon dioxide (PETCO2) and mean arterial pressure (MAP) during hypercapnia in 
RIPC and sham conditions (mean ± SD) 
 
There was no difference in MCAv and cerebrovascular conductance reactivity slopes 
between conditions (Table 2.3). 
Table 2-3: The reactivity of middle cerebral artery velocity (MCAv) and cerebrovascular 
conductance per mmHg to an increase in partial pressure carbon dioxide (PETCO2) during 
hypercapnia (mean ± SD). 
 RIPC SHAM P Values 
MCAv (cm/s/mmHg
 
) 1.86 ± 0.53 2.09 ± 0.90 0.395 
CBVC (cm/s/mmHg)  0.02 ± 0.01 0.01 ± 0.01 0.542 
Abbreviations: MCAv (middle cerebral artery velocity), CBVC (cerebrovascular conductance). 
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2.3.4. Squat-stand maneouvers 
 
Figure 2.6: An example recording from one representative individual of middle cerebral 
artery velocity (MCAv), mean arterial pressure (MAP) and end-tidal pressure of carbon 
dioxide (PETCO2) during the 0.1Hz squat-stand manoeuvres. 
 
Gain at Very Low Frequency (VLF): There was a significant main effect of  time (P<0.001) 




 under hypercapnic 
conditions (Figure 2.7). There was no main effect of conditon (P=0.142) nor time*condition 
interaction (P=0.251). There was no significant main effects or interaction for gain at very 
low frequency (Table 2.4) 
Gain at Low Frequency (LF): There was a significant main effect of time (P<0.001) with 




 under hypercapnic 
conditions (Figure 2.8). No significant main effect for condition (P=0.457) or time*condition 
43 
 
interaction was observed (P=0.098). There was a significant main effect of time (P=0.018) 





hypercapnic conditions (Table 2.4). There was no significant main effect of condition or 
interaction for gain at low frequency (Table 2.4) 
Gain at High Frequency (HF): There was a significant main effect of time (P <0.001) with a 




 under hypercapnic 
conditions. No significant main effect for condition (P=0.605) or time*condition interaction 
was observed (P=0.908) (Figure 2.9). There was no significant main effects or interaction for 
gain at high frequency (Table 2.4) 
Table 2-4: Gain determined by transfer function at very low (VLF), low (LF) and high 
frequency (HF) during repeated squat manoeuvres at 0.10 Hz whilst breathing normal room 
air and during hypercapnia. Mean ± SD.  
 RIPC SHAM Two Way ANOVA P Values 

















































Figure 2.7: Normalised gain in the very low frequency determined by transfer  function 
























Figure 2.8: Normalised gain in the low frequency determined by transfer function during 

































Figure 2.9: Normalised gain in the high frequency determined by transfer function during 









Phase at Very Low Frequency (VLF): There was a significant main effect of time (P <0.001) 
with phase decreasing by 23 (95%CI: 29, 17) radians under hypercapnic conditions (Figure 
2.10).  No significant main effect for condition (P=0.514) or time*condition interaction was 
observed (P=0.358).  
Phase at Low Frequency (LF): There was a significant main effect of time (P<0.001) with 
phase decreasing by 10 (95%CI: 14,7) radians under hypercapnic conditions (Figure 2.11).  
No significant main effect for condition (P=0.655) or time*condition interaction was 
observed (P=0.966).  
Phase at High Frequency (HF): There was no significant main effect for condition (P=0.914), 








































Figure 2.10: Phase in the very low frequency determined by transfer function during repeated 










Figure 2.11: Phase in the low frequency determined by transfer function during repeated 

































Figure 2.12: Phase in the high frequency determined by transfer function during repeated 






Coherence: There was a signficant main effect of time with very low frequency coherance 
increasing by 0.109. There was no significant main effect of condition or condition*time 
interaction for very low frequcency coherance (Table 2.5). There was no significant main 
effects or condition*time interaction in for low and high frequency coherance. 
Table 2-5: Coherence determined by transfer function at very low (VLF), low (LF) and high 
frequency (HF) during repeated squat manoeuvres at 0.10 Hz whilst breathing normal room 
air and during hypercapnia 
 RIPC SHAM Two Way ANOVA P Values 
 Normal Hypercapnia Normal Hypercapnia Condition Time Int 
VLF  0.63 ± 0.13 0.78 ± 0.06 0.70 ± 0.20  0.77 ± 0.95 0.615 0.003  0.430 
LF 0.88 ± 0.37 0.82 ± 0.14 0.84 ± 0.08 0.82 ± 0.09 0.765 0.174 0.530 
















The aim of the present study was to determine whether 40 mins of bilateral arm RIPC could 
enhance cerebrovascular CO2 reactivity and cerebral autoregulation compared to a SHAM 
condition. This study also aimed to investigate the impact of RIPC on hypercapnia-induced 
impairment of cerebral autoregulation.  There was no effect of RIPC on cerebrovascular 
responses to CO2 reactivity or autoregulation, and RIPC did not attenuate the hypercapnia-
induced impairment in cerebral autoregulation. This study is the first to investigate the impact 
of RIPC on a range of cerebrovascular functional tests in humans. The results of this study 
suggest that an acute bout of RIPC does not impart immediate cerebrovascular benefits in 
healthy individuals. 
Despite the considerable literature on the effects of RIPC on cardiac and peripheral vascular 
function in humans, very little research work has been performed on its effect/s on 
cerebrovascular function, despite stroke and cerebrovascular disease being a leading cause of 
death worldwide (Roger et al., 2012). This may relate to the difficulties in assessing 
cerebrovascular function.  Whilst, there are a number of tests available for the assessment of 
peripheral artery function, no such specific test is available to assess cerebrovascular health. 
The intrinsic mechanisms involved in the maintenance of CBF are highly complex and 
integrated, and known to be highly sensitive to changes in perfusion pressure (blood pressure) 
and arterial gases, particularly carbon dioxide.  In this context, tests of cerebral autoregulation 
and CO2 reactivity were employed in the current study as markers of cerebrovascular 
function to best gauge the impact of RIPC. 
One novel aspect of this study was that both MAP and MCAv, as an index of CBF, were 
measured during the RIPC and SHAM stimuli to determine the direct impact of RIPC on 
cerebrovascular control. Previous research studies have demonstrated that acute exposure to 
RIPC leads to increased blood flow in conduit and resistance arteries in distant areas (such as 
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the contralateral limb) (Enko et al., 2011) or organs (e.g. the heart) (Zhou et al., 2007, 
Shimizu et al., 2007) and also to enhanced cutaneous tissue oxygen saturation and arterial 
capillary blood flow (Kraemer et al., 2011). In contrast to the previous studies, the results of 
the current study suggest that CBF is not altered during a single episode of RIPC (4 x 5 mins 
of ischemia and reperfusion). Nevertheless, blood pressure did increase transiently during the 
RIPC but this increase was also evident in SHAM.  
Cerebral autoregulation was assessed using squat-stand manoeuvres at 0.1 Hz (i.e. 6 squats 
per minute) in the current study. A single episode of RIPC employed immediately prior to the 
squat-stand manoeuvres did not alter the oscillations between CBF and MAP (transfer 
function determined gain or phase) when compared to SHAM in the current study.  In 
addition, there was no change in cerebral CO2 reactivity between conditions. Interestingly, 
the blood pressure response during hypercapnia appeared to be lower in the RIPC condition, 
whilst this was not statistically significant, this could suggest a cardio-protective role of RIPC 
in lowering the pressor response during the hypercapnic stimulus without affecting the 
magnitude of the cerebral blood flow response. Nonetheless, the apparent lack of impact of 
an acute bout of RIPC on resting cerebrovascular function may not be surprising as all but 
one previous study (Moro et al., 2011) has shown that RIPC does not acutely change 
endothelial function in conduit arteries (Loukogeorgakis et al., 2005, Kharbanda et al., 2002, 
van den Munckhof et al., 2013). It is likely that a more frequent dose of RIPC (e.g. repeated 
RIPC) is required to improve CBF and/or cerebrovascular function, given that the only other 
human RIPC studies measuring cerebrovascular outcomes employed a repeated daily RIPC 
protocol lasting 300 days (Meng et al., 2012) and 180 days (Meng et al., 2015) and found 
improvements in cerebral perfusion. Other factors that may explain the absence of an 
improvement in cerebrovascular function may relate to the group that was assessed. These 
aforementioned studies included individuals with chronic cerebrovascular dysfunction 
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(stenosis); therefore it is possible an acute cerebral benefit due to RIPC may be more likely in 
this cohort due to their lower cardiovascular health a priori. Furthermore, it is important to 
note that repeated RIPC has improved endothelial function in healthy individuals in conduit, 
resistance and cutaneous vessels (Jones et al., 2015, Jones et al., 2014, Kimura et al., 2007). 
Taken together, these results indicate that exposure to a single bout of RIPC does not affect 
cerebrovascular function in healthy individuals.  
 
This study also aimed to investigate if RIPC could attenuate or prevent hypercapnia-induced 
impairment of cerebral autoregulation, compared to a SHAM condition. Previous studies 
have suggested that a sustained period of hypercapnia (inhalation of higher levels of carbon 
dioxide) impairs cerebral autoregulation (Birch et al., 1995, Zhang et al., 1998), and thus 
cerebrovascular function. Therefore, the combination of hypercapnia and squat-stand 
manoeuvres was employed to investigate if RIPC could indeed attenuate cerebrovascular 
dysfunction. The inhalation of a higher level of CO2 caused alterations in the oscillations 
between CBF and MAP shown via a decrease in phase determined via transfer function 
analysis, which suggests that hypercapnia was successful in causing impaired cerebral 
autoregulation. Nevertheless, and contrary to the hypothesis, RIPC did not attenuate this 
impairment compared to SHAM. There are a number of potential reasons for the lack of 
effect of RIPC on cerebral autoregulation during hypercapnia. Firstly, RIPC is known to 
show two windows of protection with the first window lasting 2-3 hours after the RIPC 
stimulus, and a second window appearing 24 hours post RIPC and lasting up to 72 hours 
(Heusch et al., 2015). The previous studies exploring the impact of RIPC on cerebrovascular 
dysfunction in animal models (e.g. experimental models of inducing a stroke) have focused 
on the second window of protection whereby cerebrovascular dysfunction has been assessed 
48-72 hours following the RIPC stimulus (Hoyte et al., 2006, Ren et al., 2008). In this study, 
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assessment of cerebrovascular function was planned approximately 10 minutes after RIPC. 
Whether differences in the timing and/or efficacy of the window(s) of protection are present 
between coronary and cerebral vessels is currently unknown. Some, but not all, previous 
research studies, albeit investigating the impact of RIPC on exercise performance, have 
suggested that RIPC requires a longer period than used in this current study to offer 
significant beneficial effects (Bailey et al., 2012). Therefore, it is possible that in the current 
study cerebrovascular measurements and cerebral dysfunction may have been employed too 
soon following the RIPC bout. 
One final explanation may be related to the dose and timing of the hypercapnia that was 
employed to cause cerebrovascular dysfunction. It is possible that a higher level of CO2 (e.g. 
6%) (Coverdale et al., 2016) or inhalation for a longer time period may have induced a 
greater level of cerebrovascular dysfunction. Given that a decrease in gain determined via 
transfer function was observed during hypercapnia in both RIPC and SHAM conditions, 
which is usually associated with more efficient cerebral autoregulation (van Beek et al., 
2008), it is plausible that a sufficient decrease cerebrovascular dysfunction was not induced. 
Additionally, this decrease in both gain and phase may outline that rather than inducing a 
dysfunction to cerebral autoregulation with hypercapnia, an offset to the timing of 
autoregulation occurred instead.  
Conflicting responses in transfer function outputs (i.e. gain and phase) may potentially be as a 
result of methodological differences between this study and previous studies. Whilst Zhang et 
al. (1998) employed a high percentage of CO2 inhalation during autoregulation, this current 
study started 5% CO2 four minutes prior to autoregulation, therefore the immediate responses 
to gas concentration may have already occurred before autoregulation had begun, as opposed 
to during the assessment of autoregulation (Zhang et al., 1998). Additionally, differences in 
how cerebral autoregulation was assessed itself may have caused the conflicting response in 
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transfer function gain, with previous a study adopting the rapid thigh cuff technique (Zhang 
et al., 1998) as opposed to the more modern squat-stand technique used in this current study. 
Regardless, hypercapnia was sufficient in altering the cerebro-functional response to 
autoregulation, and as the response following RIPC was not different, it suggests RRIPC did 
not affect cerebrovascular function. 
 
2.4.1. Methodological Considerations 
As is inherent in the use of TCD, it is assumed that the diameter of the imaged vessel does 
not change, which may have influenced the findings of the current study, particularly during 
hypercapnia.  Nevertheless, the absolute CO2 reactivity responses between the IPC and Sham 
conditions were similar, indicating similar cerebrovascular responses. This suggests that if 
the MCA dilated, it was likely to have dilated to the same extent in both conditions, and 
therefore the within-subject comparison between conditions remains robust.  
 
2.4.2. Clinical Perspectives: 
Impairment in cerebrovascular function can lead to serious conditions, such as dementia, 
cognitive impairment and stroke. With recent clinical trials showing that repeated RIPC can 
reduce stroke patients future susceptibility to strokes (Meng et al., 2012, Meng et al., 2015), it 
indicates that despite the results from this study, RIPC could have a cerebral/neural impact 
that offers a non-invasive, simple and inexpensive strategy to improve clinical consequences 
of stroke in humans. Therefore, the impact of (R)IPC on cerebrovascular function warrants 
further research.  
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2.4.3. Future Directions: 
Despite RIPC having no impact on cerebrovascular function in this study, there is still much 
to explore regarding IPC and the cerebrovascular system. Moving forward, future studies 
should consider the timing of the RIPC stimulus in relation to the timing of examination of 
cerebrovascular function. RIPC generates two separate windows of protection, therefore 
future studies should consider examining cerebrovascular function on multiple occasions to 
more comprehensively examine the impact of RIPC.  In addition, it is possible that the level 
of impairment in cerebrovascular function induced by the hypercapnia was not sufficient 
enough to determine whether RIPC can attenuate any potential difference. Therefore future 
studies may also induce a greater state of hypercapnia, either by using a higher CO2% and/or 
duration.  Healthy individuals were assessed in the current study and it could be argued that 
no effect of IPC was observed due to the fact their cerebrovascular function cannot be 
significantly improved on, therefore repeating the current study in a clinical group with 
vascular dysfunction may ‘un-mask’ the effect of IPC on cerebrovascular function. Finally, 
future studies should consider the dosage of the RIPC applied, with repeated bouts potentially 
providing a more potent and longer lasting effect (Przyklenk and Whittaker, 2011).   
Conclusion 
In summary, this study reports that an acute bout of bilateral arm RIPC did not alter cerebral 
blood flow or enhance cerebral CO2 reactivity or autoregulation, compared to a SHAM 
condition in healthy individuals. In addition, RIPC did not attenuate the impairment in 
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